为了治疗晚期子宫内膜癌症,减少了连续服用 pembrolizumab 的 lenvatinib 的剂量
Quang D Ta1, Connie Do2, Kavita Sharma3
1Kaiser Permanente Diablo Service Area, Walnut Creek, CA, United States.
Gynecologic oncology
|April 2, 2025
概括
较低的伦瓦提尼布剂量与潘布罗利祖马布相结合,对子宫内膜癌患者表现出类似的有效性. 较低的初始剂量可以通过减少剂量修改而提高耐受性,而不会影响无进展生存率.
科学领域:
- 在瘤学瘤学.
- 临床药理学 临床药理学
背景情况:
- 子宫内膜癌的治疗通常涉及组合疗法.
- 伦瓦提尼布和 pembrolizumab 组合用于晚期子宫内膜癌.
- 优化伦瓦提尼布剂量对于安全性和有效性至关重要.
研究的目的:
- 为了评估减少lenvatinib剂量与pembrolizumab相结合的安全性和有效性.
- 为了比较患有不匹配修复能力 (MMRp) 晚期子宫内膜癌的患者接受不同初始林瓦提尼布剂量的结果.
主要方法:
- 对369名接受伦瓦提尼布-布罗利祖马布治疗的患者进行了回顾性队列研究.
- 根据伦瓦替尼的初始剂量分组的患者:每天20毫克,每天<20毫克,或每天20毫克5天/周.
- 主要结局:六个月无进展生存期 (PFS-6);次要结局:由于不良事件 (AE) 而减少剂量/中止治疗.
主要成果:
- 在每日20毫克和每日<20毫克的伦瓦提尼布组之间,PFS-6或中位数无进展生存 (PFS) 没有显著差异.
- 在每日20毫克的小组中,减少伦瓦替尼的剂量发生率更高 (每100人/年28.1 vs 14.3).
- 两组之间与AE相关的伦瓦提尼布剂量中止没有差异.
结论:
- 降低的初始林瓦提尼布剂量 (每天<20毫克) 与布罗利祖马布结合,在MMRp晚期子宫内膜癌中显示出相当于每天20毫克的疗效.
- 较低的伦瓦提尼布初始剂量可能更好地耐受,导致更少的剂量减少,而不会影响疗效.
- 需要进一步的研究来确定有效的伦瓦提尼布剂量的最佳下限.
相关概念视频
Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Renal Failure: Dose Adjustments
54
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
54


